Collegium Pharmaceutical (NASDAQ:COLL) Trading Down 5.3%

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s stock price was down 5.3% during trading on Wednesday . The stock traded as low as $34.70 and last traded at $34.75. Approximately 159,747 shares were traded during trading, a decline of 66% from the average daily volume of 469,928 shares. The stock had previously closed at $36.71.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on COLL shares. Truist Financial lifted their price objective on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a report on Friday, August 9th. HC Wainwright upgraded shares of Collegium Pharmaceutical from a “neutral” rating to a “buy” rating and set a $47.00 target price for the company in a research note on Tuesday, July 30th. Jefferies Financial Group upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and lifted their price target for the stock from $41.00 to $44.00 in a report on Friday, June 7th. StockNews.com raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Monday. Finally, Needham & Company LLC reissued a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Collegium Pharmaceutical Stock Down 6.6 %

The company has a quick ratio of 1.14, a current ratio of 1.21 and a debt-to-equity ratio of 1.98. The firm has a 50 day moving average of $33.27 and a 200 day moving average of $34.89. The firm has a market cap of $1.12 billion, a price-to-earnings ratio of 14.97 and a beta of 0.93.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.22. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. The company had revenue of $145.28 million during the quarter, compared to analysts’ expectations of $143.94 million. During the same period in the previous year, the business earned $1.13 earnings per share. The firm’s quarterly revenue was up 7.2% compared to the same quarter last year. As a group, sell-side analysts predict that Collegium Pharmaceutical, Inc. will post 5.73 earnings per share for the current year.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 56,807 shares of the stock in a transaction on Friday, May 24th. The stock was sold at an average price of $33.98, for a total value of $1,930,301.86. Following the completion of the sale, the executive vice president now owns 105,902 shares in the company, valued at approximately $3,598,549.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, EVP Scott Dreyer sold 56,807 shares of Collegium Pharmaceutical stock in a transaction on Friday, May 24th. The shares were sold at an average price of $33.98, for a total transaction of $1,930,301.86. Following the completion of the sale, the executive vice president now directly owns 105,902 shares in the company, valued at $3,598,549.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Colleen Tupper sold 19,710 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total transaction of $674,279.10. Following the sale, the chief financial officer now directly owns 130,845 shares of the company’s stock, valued at approximately $4,476,207.45. The disclosure for this sale can be found here. 3.98% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several large investors have recently made changes to their positions in the stock. Gladius Capital Management LP acquired a new stake in shares of Collegium Pharmaceutical in the second quarter valued at about $32,000. Principal Securities Inc. acquired a new stake in shares of Collegium Pharmaceutical in the fourth quarter worth $40,000. nVerses Capital LLC increased its position in shares of Collegium Pharmaceutical by 1,600.0% in the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $55,000 after acquiring an additional 1,600 shares in the last quarter. Assetmark Inc. boosted its stake in shares of Collegium Pharmaceutical by 25.5% in the fourth quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock valued at $168,000 after purchasing an additional 1,108 shares during the period. Finally, Sheaff Brock Investment Advisors LLC purchased a new position in shares of Collegium Pharmaceutical in the first quarter valued at $204,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.